FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to biotechnology and represents antibody which possesses ability to bind with IL-13Rα1 and inhibit biological activity of IL-13.
EFFECT: antibodies can be actively applied for treatment of asthma and allergic diseases.
6 cl, 5 dwg, 5 tbl, 17 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODIES TO INTERLEUKINE-1 RECEPTOR AND THEIR APPLICATION | 2004 |
|
RU2369617C2 |
IMMUNOGLOBULINS | 2005 |
|
RU2404192C2 |
INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
IL-17 ANTAGONIST ANTIBODIES | 2005 |
|
RU2426741C2 |
INTERLEUKIN-13 BINDING PROTEINS | 2007 |
|
RU2472807C2 |
INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
HUMAN ANTIBODIES TO IL-β1 | 2001 |
|
RU2286351C2 |
ANTIBODY AGAINST IL-4R AND APPLICATION THEREOF | 2018 |
|
RU2758091C1 |
ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
IL-17A LINKING AGENT AND METHODS FOR USE THEREOF | 2014 |
|
RU2682046C1 |
Authors
Dates
2011-03-10—Published
2006-01-02—Filed